Shares of Aurobindo Pharma were last trading 2.27 per cent lower at Rs 975.10 on the BSE.
Share Price of Aurobindo Pharma Limited edged lower by more than two per cent on Tuesday, June 1, a day after the pharmaceutical company announced its January-March quarter results for the financial year 2020-21. On Tuesday, Aurobindo Pharma opened on the BSE at Rs 1,000, inching to an intra day high of Rs 1,007.95, and an intra day low of Rs 959.90, through the trading session so far. According to a regulatory filing by the firm to the stock exchanges, Aurobindo Pharma reported a net profit of Rs 801.18 crore consolidated basis in the fourth quarter of fiscal 2020-21.
/PRNewswire/ Verified Market Research recently published a report, "Active Pharmaceutical Ingredient (API) Market" By Molecule (Small Molecule and Large.
Bringing ambulance services within the reach of the needy thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
decisivemarketsinsightsMay 10, 2021
The
Brown-Sequard Syndrome Treatment Market is expected to grow at a CAGR of 6.82% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report our experts have examined the market from a 360 degree perspective thereby producing a report which is definitely going to impact your business decisions.
In order to make a pre-order inquiry, kindly click on the link below:-
Summary of the Brown-Sequard Syndrome Treatment Market Report
In terms of both profitability and growth, how the global business environment is changing and also to ensure the continuous success in the global market, how the industry is confronting the challenges, a better understanding of the market participants is well provided in the market research industry report by Decisive Markets Insights. The
Health
your username
May 10, 2021
Amgen Inc. and its subsidiary KAI Pharmaceuticals Inc. filed a complaint in the District of Delaware last week against Aurobindo Pharma Limited and Aurobindo Pharma USA Inc. (collectively, Aurobindo), alleging that Aurobindo infringed their patents by filing for a generic version of the drug Parsabiv.
According to the complaint, Aurobindo filed Abbreviated New Drug Application (ANDA) No. 215840 to the U.S. Food and Drug Administration (FDA) “seeking approval to manufacture and sell a generic version of Parsabiv® (etelcalcetide) injection for intravenous use at strengths of 2.5mg/0.5mL, 5mg/mL, and 10mg/2mL (‘Aurobindo’s Proposed ANDA Product’)” before the plaintiffs’ patents – U.S. Patent Nos. 9,820,938 and 10,344,765 – expire. The plaintiffs stated that they were notified by Aurobindo in a letter that they received in March 2021 that it submitted the ANDA. The plaintiffs alleged that based on information and belief, Aurobindo’